Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 800 results for "amgen rank"

The Zacks Analyst Blog Highlights: Amgen, Regeneron, Nektar, A...

For Immediate Release Chicago, IL March 19, 2015 Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial ... Yahoo! Finance, 1 week ago
[x]  

3 images for "amgen rank"

Business First of Louisville, 1 week ago
Forbes.com, 2 months ago
Forbes.com, 2 months ago

Potential Amgen (AMGN) Trade Has 1.54% Downside Protection

(Marketintelligencecenter.com via COMTEX) -- The patented options-trade picking algorithms used by MarketIntelligenceCenter.com found a trading opportunity with Amgen Inc ( AMGN ) that should provide a 7.06% return in just 51 days. Sell one May.
 TradingCharts.com4 days ago Potential Amgen (AMGN) Trade Has 3.46% Downside Protection  TradingCharts.com1 week ago Potential Amgen (AMGN) Trade Targets 7.13% Return  TradingCharts.com1 week ago Amgen Inc. (AMGN), AstraZeneca PLC (AZN) Drug Data Lures Bulls  Schaeffers Research1 week ago
[x]  

Zacks Industry Outlook Highlights: Orexigen, MannKind, Amgen, Medivation and Express Scripts - Press Releases

Today, Zacks Equity Research discusses the Pharma/Bio, including Orexigen ( OREX - Free Report ), MannKind ( MNKD - Free Report ), Amgen ( AMGN - Free Report ), Medivation ( MDVN - Free Report ) and Express Scripts ( ESRX - Free Report ). ...
 Zacks.com1 week ago Zacks Investment Ideas feature highlights: Biogen, Amgen, SPDR S&P Biotech ETF, BioShares Biotechnology …  Yahoo! Finance1 week ago
[x]  

Amgen-Celimmune Tie Up for Autoimmune Disorder Drug - Analyst Blog

Amgen Inc. AMGN and Celimmune LLC have inked a deal for the development of an anti-IL-15 monoclonal antibody (AMG 714). Celimmune has obtained the candidate from Amgen under an exclusive license agreement. Under the agreement, Celimmune gained the ...
 Yahoo! Finance3 weeks ago
Examiner.com

Jens Voigt is Amgen Tour of California Ambassador

Jens Voigt , an extremely respected pro cyclist, recently retired, has been named an Ambassador for the Amgen Tour of California . The addition of this legendary cyclist to the Amgen is good news for everyone who pedals a bike. The announcement came ...
 Examiner.com4 weeks ago Lexus Brings Style and Precision to Amgen Tour of California  Yahoo! Finance1 month ago
[x]  

Amgen (AMGN) Showing Support Near $166.47

(Marketintelligencecenter.com via COMTEX) -- For a hedged play on Amgen Inc ( AMGN ) MarketIntelligenceCenter.comaEUR(TM)s algorithms selected the Jul. '15 $180.00 covered call for a net debit in the $165.75 area. That is also the break-even stock ...
 TradingCharts.com6 days ago

Amgen Seeks Approval for PCSK9 Inhibitor Repatha in Japan - Analyst Blog

Amgen Inc.AMGN announced that it is looking to get its PCSK9 inhibitor, Repatha, approved in Japan. The company has submitted a marketing application for its cholesterol-lowering candidate to the Ministry of Health, Labour and Welfare in Japan. We ...
 Nasdaq6 days ago
[x]  

Amgen Presents Encouraging PCSK9 Inhibitor Repatha Data - Analyst Blog

Amgen Inc. AMGN presented encouraging one-year data from the phase II (OSLER-1) and phase III (OSLER-2) open-label extension studies and phase III YUKAWA-2 study on its PCSK9 inhibitor, Repatha (evolocumab), at the American College of Cardiology's ...
 Zacks.com1 week ago

Amgen's Kyprolis Fares Better than Velcade in Study - Analyst Blog

Biotech major Amgen AMGN and its subsidiary Onyx Pharmaceuticals, Inc. announced that multiple myeloma drug, Kyprolis, fared well in a planned interim analysis of the phase III head-to-head ENDEAVOR (Randomiz E d, Ope N Label, Phase 3 Study of ...
 Zacks.com3 weeks ago

Amgen's Kyprolis Under EU Review - Analyst Blog

Amgen Inc'sAMGN marketing authorization application for its multiple myeloma drug, Kyprolis, has been accepted for review in the EU. The company is looking to get Kyprolis approved for the treatment of patients with relapsed multiple myeloma who ...
 Nasdaq4 weeks ago Amgen's Kyprolis Under EU Review  PredictWallStreet4 weeks ago
[x]  
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less